OpGen, Inc. (OPGN)
USD 4.04
(3.86%)
USD 4.04
(3.86%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 13.44 Million USD | -26.35% |
| 2022 | 18.25 Million USD | -40.05% |
| 2021 | 30.44 Million USD | 6.62% |
| 2020 | 28.55 Million USD | 366.02% |
| 2019 | 6.12 Million USD | 8.63% |
| 2018 | 5.64 Million USD | 8.1% |
| 2017 | 5.21 Million USD | -10.27% |
| 2016 | 5.81 Million USD | -7.26% |
| 2015 | 6.27 Million USD | -41.5% |
| 2014 | 10.72 Million USD | 114.83% |
| 2013 | 4.99 Million USD | 103.89% |
| 2012 | 2.44 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 14.53 Million USD | 6.25% |
| 2024 Q1 | 13.68 Million USD | 1.78% |
| 2023 Q1 | 17.33 Million USD | -5.04% |
| 2023 Q3 | 15.45 Million USD | -0.75% |
| 2023 Q4 | 13.44 Million USD | -13.03% |
| 2023 Q2 | 15.57 Million USD | -10.15% |
| 2023 FY | 13.44 Million USD | -26.35% |
| 2022 Q3 | 19.02 Million USD | -11.31% |
| 2022 Q1 | 30.08 Million USD | -1.19% |
| 2022 FY | 18.25 Million USD | -40.05% |
| 2022 Q4 | 18.25 Million USD | -4.03% |
| 2022 Q2 | 21.44 Million USD | -28.72% |
| 2021 Q1 | 29.12 Million USD | 1.98% |
| 2021 Q2 | 28.82 Million USD | -1.02% |
| 2021 FY | 30.44 Million USD | 6.62% |
| 2021 Q3 | 28.99 Million USD | 0.57% |
| 2021 Q4 | 30.44 Million USD | 5.03% |
| 2020 FY | 28.55 Million USD | 366.02% |
| 2020 Q3 | 27.62 Million USD | 0.23% |
| 2020 Q2 | 27.56 Million USD | 385.17% |
| 2020 Q1 | 5.68 Million USD | -7.3% |
| 2020 Q4 | 28.55 Million USD | 3.38% |
| 2019 Q3 | 7.98 Million USD | 12.41% |
| 2019 FY | 6.12 Million USD | 8.63% |
| 2019 Q4 | 6.12 Million USD | -23.27% |
| 2019 Q2 | 7.1 Million USD | -8.35% |
| 2019 Q1 | 7.75 Million USD | 37.41% |
| 2018 Q3 | 5.19 Million USD | -9.33% |
| 2018 Q4 | 5.64 Million USD | 8.63% |
| 2018 FY | 5.64 Million USD | 8.1% |
| 2018 Q1 | 5.31 Million USD | 1.77% |
| 2018 Q2 | 5.72 Million USD | 7.84% |
| 2017 FY | 5.21 Million USD | -10.27% |
| 2017 Q3 | 5.45 Million USD | -23.43% |
| 2017 Q2 | 7.12 Million USD | 27.23% |
| 2017 Q4 | 5.21 Million USD | -4.38% |
| 2017 Q1 | 5.6 Million USD | -3.67% |
| 2016 Q1 | 6.42 Million USD | 2.45% |
| 2016 Q3 | 6.3 Million USD | 6.67% |
| 2016 Q2 | 5.9 Million USD | -8.07% |
| 2016 FY | 5.81 Million USD | -7.26% |
| 2016 Q4 | 5.81 Million USD | -7.68% |
| 2015 FY | 6.27 Million USD | -41.5% |
| 2015 Q4 | 6.27 Million USD | 24.13% |
| 2015 Q2 | 2.96 Million USD | -74.1% |
| 2015 Q3 | 5.05 Million USD | 70.19% |
| 2015 Q1 | 11.46 Million USD | 6.92% |
| 2014 FY | 10.72 Million USD | 114.83% |
| 2014 Q4 | 10.72 Million USD | 150.03% |
| 2014 Q1 | - USD | -100.0% |
| 2014 Q3 | 4.28 Million USD | 0.0% |
| 2013 Q4 | 2.99 Million USD | 0.0% |
| 2013 FY | 4.99 Million USD | 103.89% |
| 2012 FY | 2.44 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aspira Women's Health Inc. | 8.62 Million USD | -55.835% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -299.366% |
| Intelligent Bio Solutions Inc. | 5.59 Million USD | -140.255% |
| Standard BioTools Inc. | 159.86 Million USD | 91.59% |
| Inotiv, Inc. | 588.04 Million USD | 97.714% |
| Prenetics Global Limited | 44.01 Million USD | 69.455% |
| Neuronetics, Inc. | 81.64 Million USD | 83.533% |
| Star Equity Holdings, Inc. | 21.67 Million USD | 37.975% |
| Castle Biosciences, Inc. | 86.54 Million USD | 84.466% |
| Psychemedics Corporation | 6.59 Million USD | -103.757% |
| RadNet, Inc. | 2.07 Billion USD | 99.352% |
| Exact Sciences Corporation | 3.32 Billion USD | 99.596% |
| IDEXX Laboratories, Inc. | 1.77 Billion USD | 99.243% |
| iSpecimen Inc. | 6.07 Million USD | -121.187% |
| Exagen Inc. | 34.25 Million USD | 60.748% |
| Bionano Genomics, Inc. | 118.24 Million USD | 88.631% |
| CareDx, Inc | 223.28 Million USD | 93.979% |
| Check-Cap Ltd. | 1.33 Million USD | -910.816% |
| Twist Bioscience Corporation | 152.97 Million USD | 91.211% |
| Guardant Health, Inc. | 1.62 Billion USD | 99.174% |
| Biodesix, Inc. | 94.51 Million USD | 85.776% |
| BioNexus Gene Lab Corp. | 1.74 Million USD | -671.775% |
| Precipio, Inc. | 3.67 Million USD | -266.118% |
| Natera, Inc. | 691.79 Million USD | 98.057% |
| Fulgent Genetics, Inc. | 139.82 Million USD | 90.385% |
| Sera Prognostics, Inc. | 25.28 Million USD | 46.826% |
| 23andMe Holding Co. | 206.64 Million USD | 93.494% |
| OPKO Health, Inc. | 622.47 Million USD | 97.84% |
| Personalis, Inc. | 95.65 Million USD | 85.946% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | 66.579% |
| Applied DNA Sciences, Inc. | 8.77 Million USD | -53.134% |
| T2 Biosystems, Inc. | 62.83 Million USD | 78.604% |
| Neogen Corporation | 1.44 Billion USD | 99.066% |
| Myriad Genetics, Inc. | 312.9 Million USD | 95.703% |
| ICON Public Limited Company | 7.74 Billion USD | 99.827% |
| NeoGenomics, Inc. | 739.69 Million USD | 98.183% |
| Star Equity Holdings, Inc. | 21.67 Million USD | 37.975% |
| MDxHealth SA | 121.92 Million USD | 88.974% |
| Prenetics Global Limited | 44.01 Million USD | 69.455% |
| Illumina, Inc. | 4.36 Billion USD | 99.692% |
| DarioHealth Corp. | 38.24 Million USD | 64.848% |
| ENDRA Life Sciences Inc. | 1.09 Million USD | -1127.574% |
| Medpace Holdings, Inc. | 1.09 Billion USD | 98.775% |
| Mainz Biomed B.V. | 12.15 Million USD | -10.56% |
| Trinity Biotech plc | 83.38 Million USD | 83.877% |
| Sotera Health Company | 2.68 Billion USD | 99.5% |
| bioAffinity Technologies, Inc. | 3.36 Million USD | -299.366% |